AGR2 and cancer: Interestingly, the anti-adhesive effects in the hormone-sensitive MCF-7 cells featured by higher levels of PDIs were clearly more pronounced when compared to triple-negative MDA-MB-231 cells, suggesting that PDIA1-, PDIA3- and PDIA17-based therapy may represent a novel strategy for personalized anti-metastatic therapy in cancers with high PDI expression.